Drug product manu­facturing

Pre­clinical manu­facturing

At Xedev, we offer extensive preclinical manufacturing services to accelerate your drug product development – supporting you from a breakthrough molecule to an optimized formulation ready for clinical testing.

Our team specializes in scalable process development, the manufacturing of R&D batches (from very small to large batch sizes), and CMC support, ensuring you receive high-quality drug product material for proof-of-concept studies, toxicology testing, and PK/PD evaluations.

Whether you are developing formulations for biologics, small molecules, peptides or advanced drug delivery solutions, we are here to move your program forward via the most efficient route!

Batch manu­facturing of R&D batches

Preclinical manufacturing services producing R&D batches under controlled conditions
Kader

We produce preclinical material under controlled R&D (non-GMP) conditions, supporting early development studies such as toxicology, or pharmacokinetics, PK/PD studies. Through collaborations with trusted partners for the execution of these types of in vivo studies, we offer complete preclinical evaluation. Our development and manufacturing processes are designed to be fully scalable, enabling a smooth transfer from preclinical to clinical manufacturing.

All produced materials at Xedev are tested using our in-house analytical technologies to ensure the required quality, consistency, and stability of your preclinical drug product supported with the appropriate documentation.

We understand the varying needs of early development. That is why we offer flexible manufacturing amounts ranging from grams to kilograms quantities, ensuring your project receives exactly what it needs, and always aligned with your project timelines.

Choose Xedev to accelerate your timelines and confidently advance from preclinical to clinical manufacturing.

Want to learn more about clinical manufacturing?

Interested in our analytical services?

Ready to discuss your project? Contact our experts today.